These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30691536)

  • 1. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).
    Machiels JP; Salazar R; Rottey S; Duran I; Dirix L; Geboes K; Wilkinson-Blanc C; Pover G; Alvis S; Champion B; Fisher K; McElwaine-Johnn H; Beadle J; Calvo E
    J Immunother Cancer; 2019 Jan; 7(1):20. PubMed ID: 30691536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
    Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
    Garcia-Carbonero R; Salazar R; Duran I; Osman-Garcia I; Paz-Ares L; Bozada JM; Boni V; Blanc C; Seymour L; Beadle J; Alvis S; Champion B; Calvo E; Fisher K
    J Immunother Cancer; 2017 Sep; 5(1):71. PubMed ID: 28923104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).
    Fakih M; Harb W; Mahadevan D; Babiker H; Berlin J; Lillie T; Krige D; Carter J; Cox C; Patel M; Parfitt L; Powell M; Rosen L
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
    Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
    Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
    Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
    Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.
    Illingworth S; Di Y; Bauzon M; Lei J; Duffy MR; Alvis S; Champion B; Lieber A; Hermiston T; Seymour LW; Beadle J; Fisher K
    Mol Ther Oncolytics; 2017 Jun; 5():62-74. PubMed ID: 28480328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).
    O'Cathail SM; Davis S; Holmes J; Brown R; Fisher K; Seymour L; Adams R; Good J; Sebag-Montefiore D; Maughan T; Hawkins MA
    Radiat Oncol; 2020 Jun; 15(1):151. PubMed ID: 32532291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.
    Laurie SA; Bell JC; Atkins HL; Roach J; Bamat MK; O'Neil JD; Roberts MS; Groene WS; Lorence RM
    Clin Cancer Res; 2006 Apr; 12(8):2555-62. PubMed ID: 16638865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
    Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
    Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
    Rudin CM; Pandha HS; Zibelman M; Akerley WL; Harrington KJ; Day D; Hill AG; O'Day SJ; Clay TD; Wright GM; Jennens RR; Gerber DE; Rosenberg JE; Ralph C; Campbell DC; Curti BD; Merchan JR; Ren Y; Schmidt EV; Guttman L; Gupta S
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36669791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.
    García M; Moreno R; Gil-Martin M; Cascallò M; de Olza MO; Cuadra C; Piulats JM; Navarro V; Domenech M; Alemany R; Salazar R
    Hum Gene Ther; 2019 Mar; 30(3):352-364. PubMed ID: 30234393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
    Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
    Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.
    Chang J; Zhao X; Wu X; Guo Y; Guo H; Cao J; Guo Y; Lou D; Yu D; Li J
    Cancer Biol Ther; 2009 Apr; 8(8):676-82. PubMed ID: 19242097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.